Trial of Screening for ALOA-IgG AtheroAbzyme Test

This is a trial of screening for ALOA-IgG AtheroAbzyme Test comparing healthy, asymptomatic myocardial ischemic and acute coronary syndrome patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myocardial Ischemia Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Bahman Hospital

Beirut, Haret Hriek, Lebanon

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Healthy patients
High Risk patients or Asymptomatic myocardial Ischemic patients
Acute Coronary Syndrome patients

Exclusion criteria

None

Treatment and study plan

ALOA IgG-Elisa

Device

measurement of IgG Level in blood

ALOA IgG-AtheroAbzyme

Device

measurement of IgG in blood

Primary outcomes

Measuring the degree of oxidized low-density lipoprotein (LDL) by ALOA- IgG AtheroAbzyme in healthy and cardiovascular disease patients

Time frame: Three months

Sponsors and collaborators

Lead sponsor

Omicron Pharmaceuticals

Industry

Registry information

Official study title

Trial of Screening for ALOA-IgG AtheroAbzyme Test Comparing Healthy,Asymptomatic Myocardial Ischemic and Acute Coronary Syndrome Patients

Acronym: OP512011

Important dates

Study start: 2011
Primary completion: 2011
Study completion: 2011
First posted: Jan 10, 2011
Registry last updated: Mar 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed